1 Dennis M, Grasel S.Clinical pharmacology of gatifloxacin, a new fluoroquinolone[J]. Clinical Infect Dis, 2000;31:S51-8 2 Hosaka M, Yasue T, Fukuda H, Tomizawa H, Aoyama H, Hirai K.In vitro and in vivo antibacterial activities of AM-1166, a new 6-fluoro-8-methoxyquinolone[J]. Antimicrob Agents Chemother,1992;36:2108-17 3 Wakabayashi E, Mitsuhashi S.In vitro antibacterial activities of AM-1155, a novel 6-fluoro-8-methoxyquinolone[J]. Antimicrob Agents Chemother, 1994;38:594-601 4 Jones RN, Biedenbach DJ, ErwinME, BeachML, Pfaller MA. Activity of gatifloxacin against haemophilus influenzae and moraxella catarrhalis, including susceptibility test development, E-test comparisons, and quality control guidelines for H.influenzae[J]. J ClinMicrobiol, 1999;37:1999-2002 5 National Commettee for Clinical Laboratory Standards[S]. 2002:99-103 6 Pfaller MA, Jones RN, Doern GV, Salazar JC.Survey of blood stream infections attribute to gram-positive cocci:frequency of occurrence and antimicrobial susceptibility of isolates collected 1997 in the United States, Canada, and Latin America for the SENTRY Antimicrobial Surveillance Program[J]. DiagnMicrobiol Infect Dis, 1999;33:283-97 7 Diekema DJ, Pfaller MA, Schmitz FJ, Smayevsky J, Bell J, Jones RN, et al. Survey of infections due to staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe,the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997-1999[J]. Clin Infect Dis, 2001;32:(Suppl 2):S114-32 |